Wednesday, July 8, 2026

Patent intelligence · US

US 11083635

Tampon delivery system for a pharmaceutical, holistic or medicinal component

granted A61KA61K31/658A61K9/0036
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 15
Applicant portfolio 52
Patent details — US 11083635
Jurisdiction
US
Status
granted
Grant date
Aug 10, 2021
Expiration
Aug 5, 2041
Applicant
Herphoric, Inc.
Claims
25
CPC classes
A61K, A61K31/658, A61K9/0036
View on Google Patents ↗

Quick answer

US 11083635 (Tampon delivery system for a pharmaceutical, holistic or medicinal component) is held by Herphoric, Inc.. Status: granted. Granted Aug 10, 2021. Expires Aug 5, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Herphoric, Inc.
Grant date
Expiration
Claims
25
CPC classes
A61K, A61K31/658, A61K9/0036

More from Herphoric, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12312339

    Polo like kinase 4 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires May 22, 2045

    granted
  2. US 12239729

    TRPV3 agonists for the treatment of skin conditions

    Soricimed Biopharma Inc. · Expires Feb 27, 2045

    granted
  3. US 12054556

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Expires Aug 1, 2044

    granted
  4. US 12018043

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires Jun 20, 2044

    granted
  5. US 12005080

    Method for promoting proliferation of immune cells

    Oricell Therapeutics Co., Ltd. · Expires Jun 6, 2044

    granted
  6. US 11993655

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Expires May 23, 2044

    granted
  7. US 11858915

    Polo like kinase 4 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires Dec 28, 2043

    granted
  8. US 11807658

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires Nov 2, 2043

    granted

Frequently asked questions

What is US patent 11083635?

US 11083635 (Tampon delivery system for a pharmaceutical, holistic or medicinal component) is held by Herphoric, Inc.. Status: granted. Granted Aug 10, 2021. Expires Aug 5, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11083635?

Herphoric, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.

When does US 11083635 expire?

Our index shows an expiration date of Aug 5, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.